Suppr超能文献

高密度脂蛋白通过激活清道夫受体BI刺激细胞进入,从而抑制丙型肝炎病毒中和抗体。

High density lipoprotein inhibits hepatitis C virus-neutralizing antibodies by stimulating cell entry via activation of the scavenger receptor BI.

作者信息

Dreux Marlène, Pietschmann Thomas, Granier Christelle, Voisset Cécile, Ricard-Blum Sylvie, Mangeot Philippe-Emmanuel, Keck Zhenyong, Foung Steven, Vu-Dac Ngoc, Dubuisson Jean, Bartenschlager Ralf, Lavillette Dimitri, Cosset Francois-Loïc

机构信息

INSERM, U758, 69007 Lyon, France.

出版信息

J Biol Chem. 2006 Jul 7;281(27):18285-95. doi: 10.1074/jbc.M602706200. Epub 2006 May 4.

Abstract

Hepatitis C virus (HCV) exploits serum-dependent mechanisms that inhibit neutralizing antibodies. Here we demonstrate that high density lipoprotein (HDL) is a key serum factor that attenuates neutralization by monoclonal and HCV patient-derived polyclonal antibodies of infectious pseudo-particles (HCVpp) harboring authentic E1E2 glycoproteins and cell culture-grown genuine HCV (HCVcc). Over 10-fold higher antibody concentrations are required to neutralize either HCV-enveloped particles in the presence of HDL or human serum, and less than 3-5-fold reduction of infectious titers are obtained at saturating antibody concentrations, in contrast to complete inhibition in serum-free conditions. We show that HDL interaction with the scavenger receptor BI (SR-BI), a proposed cell entry co-factor of HCV and a receptor mediating lipid transfer with HDL, strongly reduces neutralization of HCVpp and HCVcc. We found that HDL activation of target cells strongly stimulates cell entry of viral particles by accelerating their endocytosis, thereby suppressing a 1-h time lag during which cell-bound virions are not internalized and can be targeted by antibodies. Compounds that inhibit lipid transfer functions of SR-BI fully restore neutralization by antibodies in human serum. We demonstrate that this functional HDL/SR-BI interaction only interferes with antibodies blocking HCV-E2 binding to CD81, a major HCV receptor, reflecting its prominent role during the cell entry process. Moreover, we identify monoclonal antibodies targeted to epitopes in the E1E2 complex that are not inhibited by HDL. Consistently, we show that antibodies targeted to HCV-E1 efficiently neutralize HCVpp and HCVcc in the presence of human serum.

摘要

丙型肝炎病毒(HCV)利用血清依赖性机制来抑制中和抗体。在此,我们证明高密度脂蛋白(HDL)是一种关键的血清因子,它能减弱单克隆抗体以及HCV患者来源的多克隆抗体对携带真实E1E2糖蛋白的感染性假病毒颗粒(HCVpp)和细胞培养产生的真正HCV(HCVcc)的中和作用。在HDL或人血清存在的情况下,中和HCV包膜颗粒需要的抗体浓度要高出10倍以上,并且在饱和抗体浓度下,感染滴度降低不到3 - 5倍,而在无血清条件下则完全抑制。我们表明,HDL与清道夫受体BI(SR - BI)相互作用,SR - BI是一种推测的HCV细胞进入辅助因子,也是介导HDL脂质转运的受体,这会强烈降低HCVpp和HCVcc的中和作用。我们发现HDL激活靶细胞可通过加速其胞吞作用来强烈刺激病毒颗粒的细胞进入,从而消除1小时的时间延迟,在此期间细胞结合的病毒粒子不会被内化,因而可被抗体靶向。抑制SR - BI脂质转运功能的化合物能完全恢复人血清中抗体的中和作用。我们证明这种功能性HDL/SR - BI相互作用仅干扰抗体阻断HCV - E2与主要HCV受体CD81的结合,这反映了其在细胞进入过程中的重要作用。此外,我们鉴定出针对E1E2复合物中HDL不抑制的表位的单克隆抗体。一致地,我们表明针对HCV - E1的抗体在人血清存在的情况下能有效中和HCVpp和HCVcc。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验